#ASTRO25 10 years and 3 months ago I was blessed to graduate from MSKCC alongside some of the most talented individuals I have ever met. @ndesai2005 Zach Zumsteg @NaamitGerber @JohnCuaron Taught me more than they know. Residency was truly awesome, hard work and all. Been a

Check out our multi-center retrospective analysis of ablative 5-fraction SMART (@MiamiCancerInst) and 15/25-fraction HART (@MSKCancerCenter) for unresectable #pancreaticcancer @RadDocMReyngold @KateMRGuidance @DrPaulRomesser @Reeladeel @EileenMOReilly https://t.co/zfybLcsRgv

Enjoyed building this Lego #LINAC with my kids and bringing it to school for Career Day. Hopefully we inspired the next generation of #radonc !!!

Hey #radonc! Trainees seeking an up-to-date treatment guide, attendings interested in learning about MSKCC treatment approaches, and leaders looking to standardize practice across your departments: add this text to your collection! 📖☢️ @LiorBraunstein https://t.co/qFXWYy4Pmz

Very pleased that @CMSGov followed the evidence and decided to continue to allow telehealth for status checks (77427). This is clearly the right decision: it preserves access for patients and gives doctors the discretion to provide care in the way they and their patients think

Telehealth palliative care via video visits is noninferior to in-person care for improving quality of life in patients with advanced lung cancer, finds trial across 22 US Cancer centers, w/ both modalities demonstrating clinically significant improvements. https://t.co/pBRlFE11rn

Radiation oncology care provided by fully remote clinicians was safe and feasible, with no serious patient events, finds cohort study.

Most insurance denials in radiation oncology were ultimately approved upon appeal; however, radiation technique and/or effectiveness may be compromised by payer-mandated changes, this cohort study of insurer-denied cases finds. https://t.co/LUlv4YGOuB @MSK_RadOnc

New in @JAMANetworkOpen: Most insurance #priorAuthorization denials for #radiation were ultimately reversed on appeal; however, ☢️technique &/or effectiveness may be compromised by payer-mandated changes➡️ delays, ⬇️dose, or less conformal tx delivery. https://t.co/waGeOMwFWg

🚨Very excited to share our work on remote management of #radonc patients now in @JAMANetworkOpen. Over 2800 patients managed remotely had high satisfaction with no major safety events, lower out of pocket costs and a reduced carbon footprint. https://t.co/wdGLsYF3hv

👀👀 Check out our latest work on #telemedicine use in #radonc and how it can help increase reach to rural areas and those with higher levels of healthcare deprivation! Thanks @JCOCCI_ASCO for helping get this out! https://t.co/iFBKLqLnwL

New in @IJROBP from Dr @drothens @LiorBraunstein & the @MSKCancerCenter #radonc team: Is #APBI an option for favorable risk #Her2+ #breastCancer? This study finds excellent short-term local control for HER2+ #bcsm treated with partial breast #radiation ☢️ https://t.co/IrUlptpJ6J

🏃🏻🏃🏻‍♀️ASTRO @RO_Institute 5K 👟🎽 Congrats @Chris_JacksonMD, @JohnCuaron, David Guttmann for leading our 4th place @MSK_RadOnc team finish 🎉 And congrats to @AnnaLaVigneMD for winning again 🥇💪🏼

🙌We're excited to announce that Dr Janopaul-Naylor has joined our @MSKCancerCenter #Radonc Team & will be providing excellent care for pts with cancer in our Basking Ridge location. He will be specializing in GU as well as other cancer primaries. Welcome Dr Janopaul-Naylor!

☢️#RadOnc #Match2024 Join our 9/6 8pm ET info session for a look at why @MSKCancerCenter is one of the top residencies in the nation …and what makes the city that never sleeps the perfect place to spend the next 4 yrs 🌇☕️🥯🚕🩺🥨🧋🗽🍹🍕🌃 Register here: https://t.co/2bvYq82SGn

New in #AdvancesRO by rising PGY4 Dr Alexandra Dreyfuss: Tumor bed boost in BCT was not associated with LRR or RFS. As boosts were used more frequently in those with high-risk features, it is possible that it may have mitigated risk of recurrence. #bcsm https://t.co/fYSUQPTLLg

Featured today by @MSKLibrary: CT and cone-beam CT of ablative #radiationtherapy for #pancreaticcancer with expert organ-at-risk contours: https://t.co/NsLvfJe2kN @MelissaZinovoy @jmannMD @carlahajj_mskcc @JohnCuaron @RadDocMReyngold

So pleased to see our work in @NatureComms, led by @SkakodubAnna, @hswalch, and @KathrynTringale, with @nikolausschultz, describing the genomics and clinical outcomes of a large set of patients with NSCLC brain metastasis. @MSKCancerCenter @MSK_RadOnc https://t.co/4Dm0Y1WVpf

☢️We are pleased to announce the appointment of Dr Zachary Moore, MD, PhD as Assistant Attending in Radiation Oncology @MSKCancerCenter. Dr. Moore will treat GU cancer & metastatic disease, as well as a variety of other malignancies in Bergen/Westchester Counties & Manhattan.

New research in @NatureComms from @pike_lab, @nikolausschultz & team describe the genomics and clinical outcomes of a large set of patients with #NSCLC brain metastasis. The findings could help guide future treatment decisions.